Conclusions:
Our preclinical validation study demonstrated that MR-HIFU can safely deliver mild temperatures of 41 to 43°C in a targeted volume for 30 minutes. Our clinical imaging study illustrates that with careful patient selection and preparation, the current MR-HIFU system may provide adequate treatment depth to target recurrent rectal cancers and sufficient MR temperature mapping stability for real-time control of mild hyperthermia exposures. Clinical and Research Center, Radiotherapy and Radiosurgery, Rozzano (Milan) , Italy Purpose/Objective: Aim of this study is the evaluation of feasibility and efficacy of SBRT in the treatment of unresectable hepatocellular carcinoma (HCC). Materials and Methods: Patients with 1-3 inoperable HCC lesions with diameter ≤6cm were treated by SBRT.
PO-0710
Prescription dose was 36-75Gy in 3-6 fractions. SBRT was delivered using the volumetric modulated arc therapy technique with flattening filter free photon beams. The primary end points of this study were in-field local control (LC) and toxicity. Secondary end points were overall survival (OS) and progression free survival (PFS). Results: 43 patients with 63 HCC lesions were irradiated. All patients had Child-Turcotte-Pugh class A or B disease. Median follow-up was 8 months (range 3-43 months). Actuarial LC at 1 and 2years was 86% and 64%. An Equivalent Dose >100Gy and GTV size were significant prognostic factors for LC in univariate analysis (p<0.001 and p<0.02). Median OS was 18 months. Actuarial OS at 1 and 2 years was 78% and 45%, respectively. Univariate analysis showed that OS is correlated with LC (p<0.04), BED>100 (p<0.05) and Cumulative GTV<5cm (p<0.04). Median PFS was 8 months, with a 1-year PFS rate of 41%. Grade ≥3 toxicity was observed in 7 patients (16%). No classic RILD was observed. Conclusions: Our study show that SBRT is a safe and effective treatment for selected patients with inoperable HCC. Local control rates and toxicity profile were encouraging.
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Prediction of response to neoadjuvant chemotherapy followed by chemoradiotherapy in rectal cancer by MRI volumetry T. Purpose/Objective: Chemoradiotherapy (CRT) followed by complete surgical removal is regarded as standard of care for locally advanced rectal cancer (LARC). To further improve clinical outcome therapeutic approaches may incorporate additional agents to the standard fluorouracil (FU)-based CRT. Intensified preoperative treatment with systemic neoadjuvant chemotherapy (NACT) before conventional longcourse CRT has shown promising long-term outcome and acceptable safety profiles. However, at present, it remains challenging to reliably identify good and poor responders at an early stage in order to achieve more individualized, effective and less toxic treatment of these patients. In this study, the purpose was to investigate if magnetic resonance imaging (MRI)-assessed tumor volumetry predicts histologic tumor response to NACT and subsequent CRT in LARC.
Materials and Methods:
The treatment in this experimental study consisted of two cycles of bolus 5-FU and oxaliplatin followed by long-course radiotherapy delivered concomitantly with capecitabine and oxaliplatin, before radical surgery. Complete MRI data sets and tumor histopathology from 69 prospectively enrolled patients were analyzed. Whole-tumor volumes were contoured in T2-weighted MR images obtained pretreatment (V PRE ), after NACT (V NACT ), and after the full course of NACT followed by CRT (V CRT ). V PRE, V NACT , and tumor volume changes relative to V PRE , DV NACT and DV CRT , were calculated and correlated to histologic tumor regression grade (TRG). Results: In total, 61% of good histologic responders (TRG 1-2) to NACT followed by CRT were correctly predicted by small pretreatment tumor volumes (V PRE < 10.5 cm 3 ), large volume regressions after NACT (DV NACT > -78.2%), or small tumor volumes after NACT (V NACT < 3.3 cm 3 ). Small pretreatment volume and large volume regression after NACT identified different patients; only six patients had both small pretreatment volume and large volume regression. Small tumor volume after NACT identified the majority of good responders (n = 27), with a sensitivity of 55.1% and a specificity of 100% (area under curve = 0.84), although the combined use of all three volumetric measurements identified the most. The volume regression after completed NACT and CRT (V CRT ) was not significantly different between good and poor responders (TRG 1-2 versus TRG 3-5). Conclusions: MRI-assessed small tumor volumes following NACT, before the commencement of CRT, predicted good histologic tumor response (TRG1-2) to the completed course of NACT and CRT with high accuracy. Further, the combined use of tumor volume measurements before, during, and after NACT identified most good responders. MR volumetry may be used to improve individualized, multimodal treatment of LARC.
